Startup CytoScale Diagnostics to Commercialize UCLA's Single-Cell Protein Biomarker Platform | GenomeWeb

This story originally ran on Aug. 5.

By Adam Bonislawski

CytoScale Diagnostics, a biotech startup formed in April by recent graduates of the University of California, Los Angeles, MBA program, has licensed a chip-based microfluidic image-cytometry platform and accompanying brain tumor biomarker assay from UCLA researchers that it plans to commercialize by the end of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: parent-of-origin effects, framework to uncover clinically important mutations from whole genome sequence data, and more.

A survey of Cincinnati schoolchildren finds teenagers want to know their genetic predisposition to disease, LiveScience reports.

More and more universities are helping their researchers patent their inventions, the Los Angeles Times reports.

Cancer Research UK unveils seven 'grand challenges' that it will fund researchers to tackle.